Product/Composition:- | Eltrombopag |
---|---|
Strength:- | Tablet: 25 mg, 50 mg, 75 mg; Suspension: 12.5 mg/5 mL |
Form:- | Tablets & Oral suspension |
Reference Brands:- | Promacta® (US & EU); Revolade®(EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Eltrombopag Tablets (Promacta® / Revolade® generic) are oral TPO receptor agonists for ITP, aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg strengths. EU-GMP/USFDA compliant, ideal for B2B supply, tenders, and licensing with full CTD support.
Eltrombopag Tablets (Promacta® / Revolade® generic) are thrombopoietin receptor agonists indicated for chronic ITP, severe aplastic anemia, and HCV-related thrombocytopenia. Available in 25 mg, 50 mg, and 75 mg oral tablet strengths, the product is manufactured under EU-GMP and USFDA-compliant facilities. Offered for B2B supply, hospital tenders, and licensing deals, with full CTD dossiers, bioequivalence studies, and regulatory support. Eltrombopag is a key addition for companies supplying hematology and oncology portfolios in regulated and semi-regulated markets, supporting global access to thrombopoiesis-stimulating therapies.